{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T19:26:44Z","timestamp":1778354804041,"version":"3.51.4"},"reference-count":46,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T00:00:00Z","timestamp":1773532800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2026,3,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The purpose of this study was to assess the eligibility criteria in randomized controlled trials (RCTs) in metastatic non\u2013small cell lung cancer (NSCLC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Eligible trials were phase 3 RCTs of systemic treatments for metastatic NSCLC, registered with the World Health Organization International Clinical Trials Registry Platform and started between 2009 and 2023. The odds of selected eligibility criteria were determined with multivariable logistic regression. Trends in the use of the eligibility criteria over time were assessed with the Fisher's exact test.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 274 of 386 trials (71%) excluded patients with an Eastern Cooperative Oncology Group (ECOG) score of &gt;1; the odds of excluding these patients were higher in RCTs of chemotherapy (adjusted odds ratio [aOR], 3.46; 95% CI [confidence interval], 1.91\u20136.50;\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a0.001) and immunotherapy (aOR, 3.31; 95% CI, 1.58\u20137.21;\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a0.001) and in recent trials (aOR, 1.83; 95% CI, 1.09\u20133.10;\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a0.02). A total of 95 of 386 trials (24.6%) had an upper age limit of 85 years or younger; this was more likely in trials performed in Asia (aOR, 8.83; 95% CI, 3.27\u201328.24;\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a0.001). The proportion of trials with eligibility criteria concerning comorbidities did not significantly decrease over time (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&gt;\u00a0.05). None of the trials had any eligibility criteria concerning frailty.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The eligibility criteria in phase 3 RCTs in metastatic NSCLC continue to be strict. In some trials, judicious modifications of these criteria should be considered to improve the enrollment of clinically relevant populations of patients, especially older adults, individuals with an ECOG score of 2, and those with selected comorbidities.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cncr.70361","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T16:46:11Z","timestamp":1773679571000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Eligibility criteria in phase 3 randomized controlled trials in metastatic non\u2013small cell lung cancer"],"prefix":"10.1002","volume":"132","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5256-1959","authenticated-orcid":false,"given":"Jan","family":"Borysowski","sequence":"first","affiliation":[{"name":"Department of Clinical Immunology Medical University of Warsaw  Warsaw Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danuta","family":"K\u0142osowska","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology Medical University of Warsaw  Warsaw Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marek","family":"Harhala","sequence":"additional","affiliation":[{"name":"Institute of Human Biology and Evolution, Faculty of Biology Adam Mickiewicz University  Poznan Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Knetki\u2010Wr\u00f3blewska","sequence":"additional","affiliation":[{"name":"Department of Lung Cancer and Thoracic Tumors Maria Sklodowska\u2010Curie National Research Institute of Oncology  Warsaw Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maciej","family":"Krzakowski","sequence":"additional","affiliation":[{"name":"Department of Lung Cancer and Thoracic Tumors Maria Sklodowska\u2010Curie National Research Institute of Oncology  Warsaw Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,3,16]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.0379"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201020\u20103852"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.1854"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.7916"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.1664"},{"key":"e_1_2_8_7_1","volume-title":"Cancer Clinical Trial Eligibility Criteria: Performance Status: Draft Guidance for Industry, IRBs, and Clinical Investigators","year":"2024"},{"key":"e_1_2_8_8_1","volume-title":"Cancer Clinical Trial Eligibility Criteria: Patients With Organ Dysfunction or Prior or Concurrent Malignancies","year":"2020"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201020\u20103857"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586\u2010021\u201003430\u20105"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2300236"},{"key":"e_1_2_8_12_1","unstructured":"International Clinical Trials Registry Platform (ICTRP).World Health Organization. Accessed April 23 2025.https:\/\/www.who.int\/tools\/clinical\u2010trials\u2010registry\u2010platform"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10120\u2010025\u201001653\u20103"},{"key":"e_1_2_8_14_1","unstructured":"About ClinicalTrials.gov. ClinicalTrials.gov. Accessed April 22 2025.https:\/\/www.clinicaltrials.gov\/about\u2010site\/about\u2010ctg"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017\u20100687"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2014\u20100093"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916\u2010023\u201002947\u2010y"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2022.02.027"},{"key":"e_1_2_8_19_1","volume-title":"R: A Language and Environment for Statistical Computing","year":"2024"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.232"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00721"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02118"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520\u2010019\u201005261\u20107"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2014\u20100247"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3181622c17"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc\u20102020\u2010001007"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2024.102693"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.55.0418"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40980\u2010020\u201000061\u20108"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj\u20102023\u2010076529"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.35772\/ghm.2019.01011"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.04.028"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.2147\/CIA.S365494"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1136\/thorax\u20102024\u2010BTSabstracts.14"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201701\u2010030OC"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01721\u20102016"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.7260"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2022.06.005"},{"key":"e_1_2_8_39_1","first-page":"11","volume-title":"ESMO Handbook of Cancer Treatments in Special Clinical Situations","author":"Peyrade F","year":"2013"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI170503"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2016.05.031"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1200\/GO.23.00483"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17071253"},{"key":"e_1_2_8_44_1","volume-title":"Cancer Clinical Trial Eligibility Criteria: Brain Metastases","year":"2020"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01777"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2019.11.001"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019\u20100166"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.70361","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cncr.70361","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.70361","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T04:39:54Z","timestamp":1775536794000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.70361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,15]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,3,15]]}},"alternative-id":["10.1002\/cncr.70361"],"URL":"https:\/\/doi.org\/10.1002\/cncr.70361","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,15]]},"assertion":[{"value":"2025-05-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70361"}}